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Electroacupuncture (EA) has been used to suppress heroin craving in addicts and the conditioned place preference (CPP)
for morphine in the rat.tempspacetempspaceThe question remained whether EA by itself will produce some rewarding
eﬀect.tempspacetempspaceThis was investigated using the CPP procedure in the present study.tempspacetempspaceThe results
indicated that rats showed a signiﬁcant preference to the 2Hz EA-paired compartment.tempspacetempspaceThis rewarding eﬀect
of EA was prevented by pre-treatment with the opioid receptor antagonist naloxone [2mg kg−1, intraperitoneally (i.p.)], CB1
cannabinoid antagonist AM251 (3μg per rat, intracerebroventricularly) or D1 dopamine receptor antagonist SCH23390 (0.1 mg
kg−1, i.p.), respectively. TempspacetempspaceIt is concluded that 2Hz EA is capable of inducing CPP in the rat via the activation
of the endogenous opioid-, cannabinoid- and dopamine-systems.
1.Introduction
Electroacupuncture (EA), being more eﬀective than the
manual acupuncture [1], has been documented to be a safe,
gentle and eﬀective approach for treating various kinds of
diseasesorsymptomssuchasacuteandchronicpain[2].Our
recent studies have demonstrated that EA could also serve as
a potential treatment for opioid addiction. For example, EA
or acupoint nerve stimulation could ameliorate withdrawal
syndrome and craving for drug in heroin addicts [3–5],
inhibit the expression of morphine-induced conditioned
place preference (CPP) in rats [4–6] and postpone the
relapse of drug reuse in detoxiﬁed former heroin addicts
[5]. Notably, the EA’s inhibitory eﬀect on the expression
of morphine-induced CPP could be blocked by opioid
receptor antagonist naloxone (1mgkg−1, intraperitoneally
(i.p.)), suggesting that this eﬀect is mediated by endogenous
opioid system possibly via μ-receptor [7]. In addition, direct
evidence has been obtained that low frequency (2Hz) EA
could increase the release of enkephalins in CNS, which
interacts with μ-a n dδ-opioid receptors [8, 9]. Since
endogenous opioid peptides in CNS are known to have
rewardingeﬀect[10,11],wewonderifEApersecouldinduce
CPP. Considering the complex network system in the CNS,
theeﬀectofEAmaybemediatednotonlybytheendogenous
opioid system but also by some other related systems
in the brain. Thus, the involvement of endocannabinoid
system is suggested since morphine-induced CPP in rats
could be blocked by SR141716A, a canabinoid receptor 1
(CB1) antagonist [12, 13], and the possible involvement
of dopaminergic transmission is suggested by the fact that
EA-induced CPP was blocked by D1 dopamine receptor
antagonist [14]. Both the endocannabinoid system and
mesolimbic dopamine system then were considered in the
present study.
2. Methods
2.1. Animals. Male Sprague–Dawley rats (8- to 10-weeks-
old) were obtained from the Peking University Experimental
Animal Center, weighing 180–220g at the beginning of the
experiment. Animals were housed four per cage in a 12:12h
light/dark cycle (lights on at 07:00) with food and water
available at all times. The room temperature was maintained
at 21–23◦C and relative humidity at 45–50%. Animals were
conditioned and tested during the light phase of the cycle.2 Evidence-Based Complementary and Alternative Medicine
They were handled daily during the ﬁrst week after arrival.
All experimental procedures were approved by the Animal
Use Committee of the Peking University Health Science
Center.
2.2.IntracerebroventricularInjection. Theanimalswereanes-
thetized with sodium pentobarbital (40mgkg−1, i.p.) and
positioned in a Kopf stereotaxic instrument. The 24-gauge
stainless steel guide cannulae were placed bilaterally to the
lateralventriclesaccordingtotheatlasofPaxinosandWatson
[15]. The coordinates were set as follows: 0.8mm posterior
to bregma, 1.6mm lateral to midline and 4mm ventral to
the surface of the cortex. Cannulae were secured to the skull
by jewelers’ screws with dental acrylic. To prevent clogging,
stainless steel stylets (27 gauge) were placed in the guide
cannulae until the animals were given the intracerebroven-
tricular (i.c.v.) injection. All animals were allowed 5 days for
recovery from surgery. For drug infusion, the animals were
gently restrained by hand; the stylets were removed from the
guide cannulae and replaced by 27-gauge injection needles,
extending the injection needle 0.5mm below the tip of the
guide cannula in the i.c.v. injection. Each i.c.v. injection unit
was connected by polyethylene tubing to a 10μlH a m i l t o n
syringe. The lateral ventricles were infused with a 4μl
solution (4μl/rat) over a 2-min period. The injection needle
was left in place for an additional 60s to allow diﬀusion, and
then the stylet was reinserted into the guide cannula.
2.3. Drugs. Naloxone HCl, SCH23390 and eticlopride (all
obtained from Sigma, USA) were dissolved in 0.9% saline,
respectively and injected i.p. to the rats. AM251 (Tocris,
Avonmouth Bristol, UK) was dissolved in 99.9% DMSO
(Sigma,St.Louis,MO,USA)fori.c.v.injection.Theinjection
volume was 4μl followed by a 5μl saline ﬂush, to be
completed in 3min.
2.4. Conditioned Place Preference. Place conditioning was
conducted in a three-compartment apparatus with an unbi-
ased design. The apparatus was a rectangular black PVC box
(75 ×22 ×30cm3) divided into threechambersseparated by
guillotine doors. The two end chambers (30 × 22 × 30cm3)
used for conditioning were connected by a smaller center
chamber (15 × 22 × 30cm3). The two end chambers were
distinguished from each other in two ways. One had a group
offourlightsarrangedinasquarepatternontheendwalland
a stainless steel mesh ﬂoor (1.3 × 1.3cm3), whereas the other
had the lights arranged in a triangle form on the wall and a
rod ﬂoor (1.3cm apart) [16]. The center chamber had gray
walls and a smooth ﬂoor. Fifteen infrared beams spaced 5cm
apart were monitoring the motion of the rat. The infrared
sensors communicated to a computer every 100ms through
an interface. All experimental events were controlled and
recorded automatically by the computer and the interface
was located in the same room. The computer also provided
continuous white noise served to mask external sounds.
The CPP procedure consisted of three phases including
pre-test, conditioning and test. Prior to the start of experi-
ment, the subjects were handled (2min per rat) twice daily
(at 8:00 A.M. and 2:00 P.M.) for 5 days. On the pre-test
day (Day 0), rats were placed individually in the center
chamber with the guillotine doors removed. They were
allowed to freely explore the entire apparatus for a 15-min
session. The amount of time spent in each compartment
was recorded automatically. Rats that spent more time (over
100s) in one of the end chambers than the other, and those
that spent more than 300s in the middle chamber were
excluded from the experiment. Over the next 10 sessions
(two sessions per day) subjects received a double-alternating
sequence of diﬀerential conditioning. In the morning, rats
were directly placed in the compartment assigned as “non-
EA” for 45min. In the afternoon (6h later), rats were treated
with EA and placed in the compartment assigned as “EA”.
After each conditioning session, the rats were returned to
their home cages and the entire apparatus was cleaned with
alcohol wipes to minimize trapped odors. On the test day
(Day 6) 24h after the last training, rats in every group
were tested under the conditions used for pre-test without
any treatment [16]. Then by using a factor of correction
(factor of correction = 900/(time spent in EA-paired + time
spent in non-EA-paired compartment), the time spent in the
central compartment was proportionally divided between
the two conditioning compartments. That is to say, the
corrected time in each conditioning compartment amounts
to the recorded time multiplied by the factor of correction.
So the total corrected time spent in both conditioning
compartment always amounts to 900s, and it is suﬃcient to
analyse the time spent in just one compartment [17].
2.5. Electroacupuncture. Rats were kept in special holders
with their hind legs and tails exposed [9]. Two stainless
steel needles of 0.3mm diameter were inserted into each
hind leg in the acupoints ST36 (5mm lateral to the anterior
tubercleofthetibia)andSP6(3mmproximaltothesuperior
border of the medial malleolus, at the posterior border of the
tibia).Constantcurrentsquare-waveelectricstimulationwas
produced by a HANS LH-800 programmed pulse generator
(Beijing Astronautics and Aeronautics Aviation University,
Beijing, China). The frequency of EA was set at 2Hz. The
intensity was increased stepwise from 0.5 to 1mA and ended
at 1.5mA, with each step lasting for 10min. To control the
unavoidable eﬀects of restraint stress from EA treatment, the
subjects of the restraint group were simply restrained in the
holder for 30min.
2.6. Data Analysis. In the CPP test, data of the time spent
in EA-paired compartment were presented as mean ± SEM.
One-way analysis of variance (ANOVA) was used to analyze
the time spent in the target compartment. When signiﬁcant
diﬀerences were found, post hoc analyses were conducted
using Student-Newman-Keul’s test. The accepted level of
statistical signiﬁcance is P < .05.
3. Results
The pre-conditioning test showed that most animals (75%)
spent an equal amount of time in the two end chambers and
less time in the small center choice chamber. After the pre-














































Figure 1: CPP induced by EA. ∗P < .05, compared with the blank
group; #P < .05, compared with the restraint group (n = 12–15).
One-way ANOVA followed by Student-Newman-Keul’s test.
of the end chambers than the other and that spent >300s in
the middle chamber were excluded from the experiment, so
the rats used in our research were truly unbiased in terms of
chamber preferences (data not shown).
3.1. EA per se could Induce CPP. On the unbiased condition,
rats were divided into three groups: blank group, restraint
group and EA group. Rats of blank group received no
treatment prior to each conditioning session, rats in restraint
group were restrained in holders for 30min without EA
a n dr a t si nE Ag r o u pw e r et r e a t e dw i t hE Af o r3 0 m i n
prior to conditioning as described in Section 2. As shown in
Figure 1, the rats received EA treatment spent signiﬁcantly
more time in EA-paired compartment than those of blank
a n dr e s t r a i n tg r o u p( P < .05, one-way ANOVA followed by
Student-Newman-Keul’s test) after 5 days of conditioning.
3.2. Endogenous Opioid Implicated in EA-Induced CPP. To
clarify if endogenous opioid implicated in EA-induced
CPP development, we test ﬁrst if naloxone administration,
45min before placing into the CPP training chamber, can
induce aversive properties. Twenty-four rats were randomly
divided two groups (naloxone and normal saline). After the
conditioning for 5 days, results showed that rats in naloxone
treatment could not display signiﬁcant CPA properties
compared with the normal saline group (data not shown).
Second, another two groups of rats were conditioned with
EA for 5 days. One group (Nx + EA) received naloxone
(2mg/kg) 15min before each EA treatment, the other
received the saline injection (Saline + EA). blank group and
restraint group wereused as controls. Figure 2 showsthatthe
establishmentofEA-inducedCPPwascompletelyblockedby
naloxone.ThetimespentinEA-associatedcompartmentwas
signiﬁcantly less in the Nx + EA group than that of saline +
EA group (P < .01), but not signiﬁcantly diﬀerent than that
of Blank and Restraint group (P > .05).
3.3. EA-Induced CPP Impaired by CB1 Antagonist AM251.
To explore whether endocannabinoids were involved in EA-
















































Figure 2: EA-induced CPP in rats was suppressed by naloxone
(2mg/kg). ∗∗P < .01, compared with saline + EA group; #P < .05,
compared with the restraint group; (n = 10–15). One-way ANOVA















































i.c.v AM251(µg)+2H zE A
Figure 3: The ﬁrst column is a control group. The dose “0” means
i.c.v. DMSO as a solvent of AM251. EA-induced CPP blocked by
i.c.v. injection of AM251 at 3μg, but not 0.3 and 1.0μgd o s e .∗P
< .05, compared with DMSO + EA group; (n = 9–11). One-way
ANOVA followed by Student-Newman-Keul’s test.
the establishment of EA-induced CPP. Forty-four rats have
been divided into four groups. Fifteen minutes before each
EA session, the DMSO + EA group were treated with DMSO
(4μl DMSO, i.c.v.), and the other three groups with diﬀerent
doses of AM251 (0.3, 1, 3μgp e r4μlp e rr a t ) ,r e s p e c t i v e l y .
The results were shown in Figure 3. An i.c.v. injection of
AM251 (at 3μg, but not 0.3 and 1.0μg dose) blocked the
establishment of EA-induced CPP.
3.4. Eﬀect of Dopamine Receptor Antagonist on EA-Induced
CPP. As shown in Figure 4, D1 dopamine receptor antago-
nist SCH23390 or its vehicle was injected 15 min before each
EA, and it was indicated that SCH23390 dose-dependently
reduced the time spent in the EA-paired compartment.
In contrast, D2 antagonist eticlopride failed to aﬀect the
expression of EA-induced CPP.4 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of dopamine receptor antagonist on the expression of CPP induced by EA. EA-induced CPP was blocked by D1 receptor




induce conditioned preference to the EA-associated com-
partment in male Sprague-Dawley rats, and this CPP could
be impaired by pre-conditioning administration of naloxone
(against μ-opioid receptor), AM251 (CB1 antagonist) and
SCH23390 (D1 antagonist). These ﬁndings suggest that 2Hz
EA may exert a reward eﬀect via activation of endogenous
opioid-, cannabinoid- and dopamine-systems in the brain’s
reward circuitry.
An accelerated release of enkephalin and β-endorphin
duringlowfrequencyEAstimulationhasbeenshownrepeat-
edly in previous studies [8, 18], and the endogenous opioids
triggered by the EA may produce a reward eﬀect, which
is supported by a recent study showing that enkepahlins
and endorphins, but not dynorphin, are involved in the
modulation of conditioned food reinforcement [10]. The
sites of action of opioids in rewarding were further iden-
tiﬁed to the hot spots in nucleus accumbens (NAc) and
ventral pallidum (VP). Opioids in NAc and VP work
together to promote and reward hedonic impact (“liking”)
to incentive motivation (“wanting”), whereas opioids in
NAc work cooperatively with other brain areas such as
lateral hypothalamus, amygdala and many other structures
to execute “wanting” behavior [11]. Also, the results in the
present study showed the dose of naloxone (2mgkg−1),
suﬃcient to block the μ-a n dδ-opioid receptors [19], could
block the EA-induced CPP, but had no signiﬁcant CPA
property, which is inconsistent with results of the previous
studies [20, 21]. This discrepancy may mainly be due to the
diﬀerence at the time point of naloxone administration. In
their works, naloxone (1 or 2mgkg−1) was injected 2min
before the rats or mice were putting into the chamber.
Whereas in our study, the rats received naloxone injection
15min before the EA session that lasted for another 30min,
so the rats were put into the CPP training chamber 45min
after the naloxone injection. In fact, Braida et al. [21]h a v e
demonstratedthatifratsunderwenttheconditioning30min
after naloxone (2mgkg−1, i.p.) treatment, they would not
express aversive properties anymore.
Endocannabinoid system in the brain has been shown
to interact with the opioid system in many physiological
activities such as anti-nociception [22], sedation/catalepsy
[23–26] and reward [21]. The latter suggests that the
rewarding properties of cannabinoids and opioids might be
functionally linked. However, it has still been controversial
whether they are connected in serial or parallel. There was
evidence that the acquisition of CPP induced by morphine
(4mgkg−1) could be dose dependently blocked by pre-
pairing administration of CB1 antagonist SR141716A (0.03–
3mgkg −1)i nr a t s[ 12, 13], suggesting that the endocannabi-
noid system may be downstream of opioid. It was also
reported that CB1 agonist CP55,940 could elicit CPP at
ad o s eo f2 0 μgkg −1, which in turn was fully antagonized
by pre-treatment with 2mgkg−1 naloxone [22], implying
that the endocanabinoind system is upstream of endogenous
opioid system. No indication can be found from our study
in this regard, since EA’s reward eﬀect could be blocked by
either CB1- or μ-receptor antagonist.
Both endogenous opioid peptides and opioid drugs are
known to enhance the release of DA in the NAc during
the induction of reward. So if EA could activate both
opioid system and endocannabioid system, it may also
activate DA system. Indeed, it has been reported that EA
can modulate the production of dopamine in the CNS
[27]. Concerning the D1 antagonist SCH23390, it has been
documented that high-dose of SCH23390 (0.5mgkg−1)c a n
induce CPA, while in our study we used the relatively small
dose (≤0.1mgkg−1), which has been shown not to induce
CPA[28].Theresultinthepresentrevealedthatthe2HzEA-
induced CPP can be blocked only by D1 dopamine receptorEvidence-Based Complementary and Alternative Medicine 5
antagonist SCH23390, but not D2 antagonist Eticlopride, at
a physiologically relevant concentration, it shows that the D1
receptormayplayamoreimportantroleinEA-inducedCPP.
Since mice lacking D2 receptors could not develop opioid-
CPP, yet behave much the same as wild-type mice in CPP
paradigmwhenfoodisusedasrewardingstimulation[29],it
seems that EA is more like a natural (e.g., food) reward than
a drug reward. Concerning the intensity of the CPP, while
EA-inducedCPPisastatisticallysigniﬁcantandreproducible
phenomenon, it is milder than morphine-induced CPP.
Taken together, since the ﬁndings suggest that 2Hz
EA could induce CPP, both endogenous opioid system
and endocannabinoid system were implicated. Activation
of the two systems may modulate dopamine system, which
enhances the associative learning in the rewarding proce-
dure.
References
[1] G. A. Ulett, S. Han, and J.-S. Han, “Electroacupuncture:
mechanisms and clinical application,” Biological Psychiatry,
vol. 44, no. 2, pp. 129–138, 1998.
[2] X. H. Chen and J. S. Han, “Analgesia induced by elec-
troacupuncture of diﬀerent frequencies is mediated by diﬀer-
ent types of opioid receptors: another cross-tolerance study,”
Behavioural Brain Research, vol. 47, pp. 143–149, 1992.
[3] J. S. Han, L. Z. Wu, and C. L. Cui, “Herion addicts treated
with transcutaneous electrical nerve stimulation of identiﬁed
frequencies,” Regulatory Peptides, vol. 54, pp. 115–116, 1994.
[4] B. Wang, B. G. Zhang, X. Ge, F. Luo, and J. S. Han, “Inhibition
by peripheral electric stimulation of the reinstatement of
morphine-induced place preference in rats and drug-craving
in heroin addicts,” Journal of Peking University (Health Sci-
ences), vol. 85, pp. 241–247, 2003.
[5] L. Z. Wu, C. L. Cui, and J. S. Han, “2/100 Hz transcutaneous
electrical stimulation for the treatment of heroine addiction,”
Journal of Beijing Medical University, vol. 31, pp. 239–242,
1999.
[6] X.-D.Shi,W.Ren,G.-B.Wang,F.Luo,J.-S.Han,andC.-L.Cui,
“Brain opioid-receptors are involved in mediating peripheral
electric stimulation-induced inhibition of morphine condi-
tioned place preference in rats,” Brain Research, vol. 981, no.
1-2, pp. 23–29, 2003.
[ 7 ]B .W a n g ,F .L u o ,Y . - Q .X i a ,a n dJ . - S .H a n ,“ P e r i p h e r a le l e c t r i c
stimulation inhibits morphine-induced place preference in
rats,” NeuroReport, vol. 11, no. 5, pp. 1017–1020, 2000.
[8] J. S. Han and Q. Wang, “Mobilization of speciﬁc neuropep-
tidesbyperipheralstimulationofidentiﬁedfrequencies,”News
in Physiological Sciences, vol. 7, pp. 176–180, 1992.
[9] J. S. Han, X. H. Chen, S. L. Sun, X. J. Xu, Y. Yuan, S. C.
Yan et al., “Eﬀect of low- and high-frequency TENS on Met-
enkephalin-Arg-Phe and dynorphin A immunoreactivity in
human lumbar CSF,” Pain, vol. 47, pp. 295–298, 1991.
[10] M. D. Hayward, A. Schaich-Borg, J. E. Pintar, and M. J.
Low, “Diﬀerential involvement of endogenous opioids in
sucrose consumption and food reinforcement,” Pharmacology
Biochemistry and Behavior, vol. 85, no. 3, pp. 601–611, 2006.
[11] K. S. Smith and K. C. Berridge, “Opioid limbic circuit for
reward: interaction between hedonic hotspots of nucleus
accumbensandventralpallidum,”JournalofNeuroscience,vol.
27, no. 7, pp. 1594–1605, 2007.
[ 1 2 ]F .C h a p e r o n ,P .S o u b r i ´ e, A. J. Puech, and M.-H. Thi´ ebot,
“Involvement of central cannabinoid (CB1) receptors in the
establishment of place conditioning in rats,” Psychopharma-
cology, vol. 135, no. 4, pp. 324–332, 1998.
[13] M. E. Singh, A. N. A. Verty, I. S. McGregor, and P. E. Mallet, “A
cannabinoid receptor antagonist attenuates conditioned place
preference but not behavioural sensitization to morphine,”
Brain Research, vol. 1026, no. 2, pp. 244–253, 2004.
[ 1 4 ]R .A .B e v i n s ,J .B e s h e e r ,M .I .P a l m a t i e r ,H .C .J e n s e n ,K .
S. Pickett, and S. Eurek, “Novel-object place conditioning:
behavioral and dopaminergic processes in expression of
novelty reward,” Behavioural Brain Research, vol. 129, no. 1-
2, pp. 41–50, 2002.
[15] G. Paxinos and C. Watson, The Rat Brain in Stereotaxic
Coordinates, Academic press, Orlando, Fla, USA, 2nd edition,
1986.
[ 1 6 ]J .H .C h e n ,J .L i a n g ,G .B .W a n g ,J .S .H a n ,a n dC .L .C u i ,
“Repeated 2 Hz peripheral electrical stimulations suppress
morphine-induced CPP and improve spatial memory ability
in rats,” Experimental Neurology, vol. 194, pp. 550–556, 2005.
[17] C. Manzanedo, M. A. Aguilar, M. Rodriguez-Arias, and J.
Minarro, “Eﬀects of dopamine antagonists with diﬀerent
receptor blockade proﬁles on morphine-induced place pref-
erence in male mice,” Behavioural Brain Research, vol. 121, pp.
189–197, 2001.
[18] J. S. Han, “Acupuncture: neuropeptide release produced by
electrical stimulation of diﬀerent frequencies,” Trends in
Neurosciences, vol. 26, pp. 17–22, 2003.
[19] E. T. Iwamoto, “Place-conditioning properties of mu, kappa,
and sigma opioid agonists,” Alcohol and Drug Research, vol. 6,
no. 5, pp. 327–339, 1985.
[20] A. Kuzmin, J. Sandin, L. Terenius, and S. O. Ogren, “Acquisi-
tion, expression, and reinstatement of ethanol-induced condi-
tioned place preference in mice: eﬀects of opioid receptor-like
1 receptor agonists and naloxone,” Journal of Pharmacology
and Experimental Therapeutics, vol. 304, pp. 310–318, 2003.
[21] D. Braida, M. Pozzi, R. Cavallini, and M. Sala, “Conditioned
place preference induced by the cannabinoid agonist CP
55,940: interaction with the opioid system,” Neuroscience, vol.
104, no. 4, pp. 923–926, 2001.
[22] J. A. Fuentes, M. Ruiz-Gayo, J. Manzanares, G. Vela, I. Reche,
and J. Corchero, “Cannabinoids as potential new analgesics,”
Life Sciences, vol. 65, no. 6-7, pp. 675–685, 1999.
[23] F. E. Pontieri, P. Monnazzi, A. Scontrini, F. R. Buttarelli,
and F. R. Patacchioli, “Behavioral sensitization to heroin by
cannabinoid pretreatment in the rat,” European Journal of
Pharmacology, vol. 421, no. 3, pp. R1–R3, 2001.
[24] F. E. Pontieri, P. Monnazzi, A. Scontrini, F. R. Buttarelli, and
F. R. Patacchioli, “Behavioral sensitization to WIN55212.2 in
ratspretreatedwithheroin,”BrainResearch,vol.898,no.1,pp.
178–180, 2001.
[25] W. L. Dewey, “Cannabinoid pharmacology,” Pharmacological
Reviews, vol. 38, pp. 151–178, 1986.
[26] L. Fattore, S. Deiana, S. M. Spano et al., “Endocannabinoid
system and opioid addiction: behavioural aspects,” Pharma-
cology Biochemistry and Behavior, vol. 81, no. 2, pp. 343–359,
2005.
[27] Q. P. Ma, Y. Zhou, and J. S. Han, “Electroacupuncture acceler-
ated the expression of c-Fos protooncogene in dopaminergic
neurons in the ventral tegmental area of the rat,” International
Journal of Neuroscience, vol. 70, no. 3-4, pp. 217–222, 1993.6 Evidence-Based Complementary and Alternative Medicine
[28] T. S. Shippenberg, R. Bals-Kubik, A. Huber, and A. Herz,
“Neuroanatomical substrates mediating the aversive eﬀects
of D-1 dopamine receptor antagonists,” Psychopharmacology,
vol. 103, no. 2, pp. 209–214, 1991.
[29] R. Maldonado, A. Saiardi, O. Valverde, T. A. Samad, B. P.
Roques, and E. Borrelli, “Absence of opiate, rewarding eﬀects
in mice lacking dopamine D2 receptors,” Nature, vol. 388, no.
6642, pp. 586–589, 1997.